Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of pazopanib
Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Gastrointestinal disease known to interfere with absorption
History of malabsorption or other clinically significant metabolic dysfunction that may interfere with absorption of oral study treatment
Gastrointestinal malabsorption, or any other condition that in the opinion of the investigator might affect the absorption of the study drug.
Must not have a gastrointestinal condition that would interfere with absorption
Malabsorption syndrome or other gastrointestinal illness that could affect oral absorption of study drugs
Has gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the Investigator.
Gastrointestinal (GI) condition which could impair absorption of study medication or inability to ingest study medication
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
Presence of conditions that will interfere significantly with the absorption of drugs
A condition that would interfere with enteric absorption
Any gastrointestinal or metabolic condition that could interfere with absorption of oral medication
Gastrointestinal condition that could interfere with the swallowing or absorption of study medication
Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs
Presence of gastrointestinal disease that would significantly affect compound absorption.
Patients with any severe gastrointestinal or metabolic condition which could interfere with the \r\nabsorption of oral study medications.
Gastrointestinal disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.
Presence of a gastrointestinal condition that may affect drug absorption
Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib
Any coexistent medical condition interfering with drug absorption
Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs
Current or recent (within 3 months) gastrointestinal disease that could impact the absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)
Subjects with significant gastrointestinal abnormalities that may affect absorption (e.g., gastric bypass, short gut syndrome).
For oral cohorts: The subject has gastrointestinal disease or has had a procedure that is expected to interfere with the oral absorption or tolerance of the study drug (e.g., functionally relevant gastrointestinal obstruction, mucositis/stomatitis, or frequent vomiting).
Has presence of a gastrointestinal condition that may affect drug absorption
Gastrointestinal abnormalities causing impaired absorption precluding administration of oral medications
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)
Presence of a malabsorption syndrome, gastrointestinal disorder, or gastrointestinal surgery that could affect the absorption of axitinib
Malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of the study drug
Patients with any condition likely to interfere with absorption of the study medication
Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
Any contraindication to oral agents or gastrointestinal disorder or procedure which expects to interfere significantly with absorption of protocol treatment.
History of gastrointestinal mal-absorption or gastric bypass surgery
Previous bowel resection anticipated to affect drug absorption
Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of this oral agent are not eligible
Known gastrointestinal disease or condition that affects the absorption of GT0918.
Active gastrointestinal conditions that are expected to impair absorption of orally administered medications
Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents
Significant gastrointestinal condition that could potentially impair the absorption or disposition of the drug
Clinically significant gastrointestinal disease, digestive dysfunction, or surgery that would compromise absorption of oral administration of medications
Patients with gastrointestinal impairment that would affect the absorption of enzalutamide or previous history of colitis
Patient has a history of gastrointestinal (GI) surgical procedures, non-surgical procedures or conditions that might interfere with the absorption or swallowing of the study drugs
Gastrointestinal condition which could impair absorption of BVD-523 or inability to ingest BVD-523
Subjects with gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the investigator
Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery or a severe gastrointestinal disease,or any other condition that investigators believe may affect absorption of the investigational product;
Patients with any severe gastrointestinal or metabolic condition that could interfere with absorption of oral medications
Any gastrointestinal (GI) disorder that may affect absorption of oral medications, such as mal-absorption syndrome or status post major bowel resection
Gastrointestinal abnormality that would affect absorption of SGN-2FF
Known gastrointestinal disease or procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease
Patients who have a history of gastrointestinal surgery or other procedures that might in the opinion of the investigator, interfere with the absorption or swallowing of the study drug
Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of lenvatinib.
Any underlying condition that would significantly interfere with the absorption of an oral medication
Unable to take oral medications or any medical condition that would interfere with the absorption of study medication capsules
Gastrointestinal disease that precludes absorption
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g, gastric bypass surgery, gastrectomy)
Gastrointestinal diseases or conditions that could affect drug absorption or could alter the assessment of safety
Gastrointestinal diseases or conditions that could affect drug absorption
Any underlying condition that would significantly interfere with the absorption of an oral medication
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Ability to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or other conditions that may hamper compliance and/or absorption of the study agent
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Current or recent (within 3 months of study treatment administration) gastrointestinal disease or conditions that could interfere with the swallowing or absorption of study medication or inability to tolerate oral medication
Have a condition that limits the ingestion or absorption of drugs administered by mouth
Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic) or have a history of abdominal surgery or other medical condition that may, in the opinion of the treating physician, interfere with gastrointestinal motility or absorption
Patients with gastrointestinal disease, or those who have had a procedure that is expected to interfere with the oral absorption or tolerance of BAL101553 (e.g., functionally-relevant gastrointestinal obstruction, or frequent vomiting unresolved upon anti-emetic supportive care), are ineligible
Subjects with gastrointestinal abnormalities including inability to take oral\n             medication, malabsorption or other conditions like chronic inflammatory bowel disease\n             that may affect absorption.
Any underlying condition that would significantly interfere with the absorption of an oral medication
Malabsorption syndrome or chronic nausea that might hinder absorption and assessment of oral medication
Patient has a history of a gastrointestinal surgery or other procedures that might, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs
Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption
Is unable to take oral medications, has a history of surgery that would interfere with the administration or absorption of oral medication, has malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of IP
Or any condition that might affect the absorption of orally taken medication
Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.
History of gastrointestinal condition that may affect drug absorption.
known gastrointestinal disease or condition which may affect the absorption of ASN003;
Any current or recent (within 3 months) gastrointestinal disease that could potentially impact the ability to swallow and/or absorb study drug (i.e., gastrointestinal surgery, malabsorption syndrome)
Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib in the opinion of the investigator
Known gastrointestinal condition that would interfere with swallowing or the oral absorption or tolerance of CUDC-907.
Active gastrointestinal conditions that are expected to impair absorption of orally administered medications
Unable to swallow oral medications, or has gastrointestinal condition deemed to jeopardize intestinal absorption.
Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting
Subjects who had major surgery to the upper gastrointestinal tract, or who have a history of inflammatory bowel disease, malabsorption syndrome, or other medical condition that may interfere with oral drug absorption.
Any medical condition or diagnosis that would likely impair absorption of an orally administered drug (e.g. gastrectomy, ileal bypass, chronic diarrhea, gastroparesis)
Patients with gastrointestinal comorbidities that would affect intake or absorption of ponatinib
Any underlying condition that would significantly interfere with the absorption of an oral medication
Gastrointestinal disease, surgery or malabsorption that could potentially impact the absorption of the study drug
Have malabsorption syndrome or other GI illness that could affect oral absorption of the study drug.
Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of lenvatinib.
Any gastrointestinal disease that could hinder the absorption of enzalutamide
Any gastrointestinal disease that could hinder the absorption of enzalutamide
Gastrointestinal condition which could impair absorption of study medication
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK medical monitor for guidance to enrol the subject;
Gastrointestinal disease that would impact on drug absorption
Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib
Gastrointestinal disease that interferes with receipt of oral drugs;
Gastrointestinal disease that would impact on drug absorption
Gastrointestinal conditions that could affect drug absorption including post surgical states such as gastric bypass
Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.
Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption
Gastrointestinal disease that may interfere with drug absorption.
Significant active gastrointestinal disease that might impair absorption of study therapy;
Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.
Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.
Gastrointestinal (GI) condition that could interfere with the swallowing or absorption of study medication
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
An upper gastrointestinal or other condition that would impair swallowing or absorption of oral medication
Active gastrointestinal (GI) conditions that might predispose to drug intolerance or poor drug absorption
Gastrointestinal condition which could interfere with the swallowing or absorption of study drug.
Any underlying condition that would significantly interfere with the absorption of an oral medication
History of gastrointestinal condition that might interfere with drug absorption
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption
Any major surgery or gastrointestinal disease that would interfere with administration of oral medications
Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.
Gastro-intestinal abnormalities that could affect the absorption of study drug.
Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
Gastrointestinal condition which could impair absorption of study medication
Clinically significant gastrointestinal abnormality that would affect absorption of the drug
Any gastrointestinal (GI) or metabolic condition that could interfere with absorption of oral medication such as ongoing grade 3 or higher diarrhea, constipation, nausea, or vomiting
Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug
Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent.
Presence of active GI disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs.
Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug
Inability to absorb abiraterone after oral administration (i.e., previous major gastrointestinal surgery or gastrointestinal disease resulting in malabsorption)
g.i. condition that would prevent ingestion or absorption of 5-FC
gastrointestinal impairment or disease that may interfere with drug absorption
Subject has difficulty taking oral medication or any digestive tract dysfunction or inflammatory bowel disease that would interfere with the intestinal absorption of drug.
Ongoing gastrointestinal medical condition such as Crohn’s disease, inflammatory bowel disease, chronic diarrhea, or chronic constipation that could interfere with absorption of oral medication
Any underlying condition that would significantly interfere with the absorption of an oral medication
Gastrointestinal conditions that may significantly affect the absorption of regorafenib
Patients with a condition that, in the opinion of the investigator, would interfere with the absorption of oral medication will be excluded from the study
Patient has any other condition that, in the opinion of the investigator, may impact the absorption of oral medications
Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
Any other condition that, in the opinion of the investigator, may impact the absorption of oral medications
Individuals with prior gastric bypass surgery or procedure that would impair absorption of nutrients
Patients with known gastrointestinal conditions that could potentially interfere with absorption of orally administered medications
Active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
History or current evidence of gastrointestinal malabsorption which, in the opinion of the investigator, may affect the extent of absorption of pritelivir.
Inability to take oral medication, or presence of a malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability of H3B-6527. Participants with prior gastric resection are eligible
History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorption
History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kava
Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of study drug.
Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.
Gastrointestinal disease
Incidence of gastrointestinal disease that may significantly alter the absorption of ACY 241.
Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide
Use of medications that alter the absorption or metabolism of levothyroxine
Not be on agents known to alter rapamycin metabolism significantly
On agents known to alter rapamycin metabolism significantly
Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug
Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide
Patient must be able to take oral medications; patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug
Subject has incidence of gastrointestinal disease that may significantly alter the absorption of LEN
Patients with impairment of gastrointestinal function that may alter the absorption of BKM120
Impairment of gastrointestinal function
Impairment of gastrointestinal function
Impairment of gastrointestinal function
Patients with impairment of gastrointestinal function or disease
History of gastrointestinal disease
Impairment of gastrointestinal function or gastrointestinal disease that may alter the absorption of sunitinib.
Gastrointestinal Function
Known impairment of gastrointestinal function that would alter drug absorption.
Impairment of gastrointestinal function/disease that may significantly alter the absorption of everolimus.
Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
Patients who have any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at risk are not eligible
Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ASTX727, or compromise completion of the study or integrity of the study outcomes.
•A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any illness, medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of lenalidomide, or put the study outcomes at undue risk
Any illness, medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib, or put the study outcomes at undue risk
Any life-threatening illness, severe and/or uncontrolled medical condition, or organ system dysfunction, laboratory abnormality, psychiatric illness or other condition which, in the Investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, put the study outcomes at undue risk or affect their participation in the study such as\r\n* Symptomatic, or history of documented congestive heart failure New York Heart Association (NYHA) functional classification III-IV (NYHA) \r\n* Corrected QT interval using Fridericia's formula (QTcF) > 470 msec (unless related to pacemaker) on echocardiogram (EKG) within 21 days of initiation of treatment\r\n* Angina not well-controlled by medication\r\n* Poorly controlled or clinically significant atherosclerotic vascular disease including cerebrovascular accident (CVA), transient ischemic attack (TIA), angioplasty, cardiac or vascular stenting within 6 months prior to enrollment
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of enzalutamide, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk
A life threatening illness, medical condition or organ system dysfunction which, in the investigators’ opinion, could compromise the subject’s safety or interfere with the absorption or metabolism of pembrolizumab
Life-threatening illness, significant organ system dysfunction, or other condition that, in the investigator's opinion, could compromise subject safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of ASTX660.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of lenalidomide capsules, or put the study outcomes at undue risk
Medical condition or organ system dysfunction which, in the investigator opinion, could interfere with absorption or metabolism of ibrutinib
Patients with any life threatening illness, medical condition or organ system dysfunction that in the opinion of the investigator could compromise the subject’s safety, interfere with absorption of metabolism of study drugs or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion could interfere with the absorption or metabolism of ibrutinib
Any medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the patient’s safety, interfere with the absorption or metabolism of ibrutinib
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk, including but not limited to:\r\n* Moderate to severe hepatic impairment (Child-Pugh classes B and C)
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-196 (acalabrutinib), or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib and/or ACP-319, or put the study outcomes at undue risk.
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ACP-196, or put the study outcomes at undue risk
A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
Any life-threatening illness, medical condition, or organ system dysfunction which, in the Investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any uncontrolled active systemic infection or any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of entinostat capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
A life threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the individual's safety or interfere with the absorption or metabolism of ENTO
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy
Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug.
Clinically significant gastrointestinal conditions or disorders that may interfere with study drug absorption, including prior gastrectomy
Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Patients who have gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug are not eligible
Subjects with gastrointestinal disorders likely to interfere with absorption of the study medication.
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
History of gastrointestinal disorders that may interfere with the absorption of study drug (including gastric bypass surgery)
Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
Gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of oral study drug(s) within 3 months of enrollment
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Clinically significant gastrointestinal disorders that may interfere with absorption of drug
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Clinically significant gastrointestinal disorders that may interfere with absorption of drug.
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Significant gastrointestinal disorders that may interfere with absorption of tosedostat.
Gastrointestinal disorders that may significantly interfere with absorption of study drug
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug as determined by the investigator
Participants with gastrectomy or pre-existing gastrointestinal disorders that may interfere with the proper absorption of the drug(s), as per conclusion of the clinical Investigator
Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea or other gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Gastrointestinal disorders or abnormalities that would interfere with absorption of study drug
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Patients with gastrointestinal disorders or abnormalities that would interfere with absorption of study treatment.
Patients with a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
Any gastrointestinal disorders which may interfere with the absorption of oseltamivir
Gastrointestinal disorders that would interfere with drug absorption
History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agent
Gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
Have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of ranolazine
History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of orally administered hormonal agents
Conditions which can result in impaired absorption, distribution, metabolism or excretion of the study treatment.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea ? Grade 2, and malabsorption syndrome).
Subject has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk for such interference (for example, short bowel syndrome or inflammatory bowel disease).
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of X-396.
For patients who are treated with oral 5-azacitidine, any gastrointestinal disorder that would interfere with the absorption, distribution, metabolism or excretion of the study drug
Significant gastrointestinal (GI) disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 751 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
Significant gastrointestinal disorder(s), that could in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 092 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs
Inability or unwillingness to swallow INCB054828 or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of INCB054828.
Treatment with drugs that have the potential to interfere with metabolism or excretion of mibefradil
Inability to swallow or retain oral medications or the presence of active GI disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of vorolanib
History of inflammatory bowel disease (e.g., Crohnis disease, ulcerative colitis),celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with absorption, distribution, metabolism, or excretion of the IP and/or predispose the subject to an increased risk of gastrointestinal toxicity.
Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
Participant has a history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism, or excretion of the IP and/or predispose the participant to an increased risk of gastrointestinal toxicity.
Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, electrocardiography (ECG) finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient; alter the absorption, distribution, metabolism or excretion of idelalisib; or impair the assessment of study results
Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy
Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, at the Investigator's discretion.
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs
History of GI perforation within 12 months prior to registration or presence of active GI disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of the study drugs
Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g. Crohn's disease, ulcerative colitis, extensive gastric resection)
History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of the stomach or small bowel that could affect absorption, distribution, metabolism or excretion of pazopanib
History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
EXPANSION COHORT ONLY: History of malabsorption syndrome, disease significantly affecting gastrointestinal function or major resection of stomach or small bowel that could interfere with absorption, distribution, metabolism, or excretion of study drugs
Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 087 (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
Presence of surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, grade ?2 diarrhea, and malabsorption syndrome).
Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, ECG finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient, alter the absorption, distribution, metabolism or excretion of the study drug, or impair the assessment of study results
Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs.
Prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, electrocardiography (ECG) finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the patient, including symptomatic hyperviscosity; alter the absorption, distribution, metabolism or excretion of ABT-199; or impair the assessment of study results
Gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications
History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the IP (INVESTIGATIONAL PRODUCT) and/or predispose the subject to an increased risk of gastrointestinal toxicity
History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of study medications.
